BioLife Solutions, Inc. (NASDAQ:BLFS) Insider Sells $27,275.00 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) insider Sarah Aebersold sold 1,091 shares of the stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total value of $27,275.00. Following the completion of the transaction, the insider now owns 58,816 shares in the company, valued at approximately $1,470,400. This represents a 1.82 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Sarah Aebersold also recently made the following trade(s):

• On Monday, January 6th, Sarah Aebersold sold 240 shares of BioLife Solutions stock. The stock was sold at an average price of $27.02, for a total transaction of $6,484.80.

BioLife Solutions Stock Performance

BLFS traded up $0.92 during midday trading on Monday, reaching $25.92. The company had a trading volume of 222,832 shares, compared to its average volume of 348,620. The business has a 50-day moving average price of $26.59 and a two-hundred day moving average price of $25.49. The company has a debt-to-equity ratio of 0.03, a quick ratio of 1.78 and a current ratio of 2.78. BioLife Solutions, Inc. has a 12-month low of $14.84 and a 12-month high of $29.55. The stock has a market cap of $1.22 billion, a PE ratio of -24.45 and a beta of 2.04.

Remove Ads

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The medical equipment provider reported $0.26 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.32. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The business had revenue of $22.71 million during the quarter, compared to analyst estimates of $21.73 million. During the same period in the prior year, the company earned ($0.21) earnings per share. On average, sell-side analysts expect that BioLife Solutions, Inc. will post -0.3 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioLife Solutions

Several institutional investors have recently added to or reduced their stakes in the business. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its position in shares of BioLife Solutions by 13.2% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 70,686 shares of the medical equipment provider's stock valued at $1,835,000 after purchasing an additional 8,258 shares during the period. Point72 Asia Singapore Pte. Ltd. bought a new stake in BioLife Solutions during the 4th quarter valued at $31,000. Point72 Asset Management L.P. purchased a new stake in shares of BioLife Solutions during the fourth quarter worth $11,113,000. ProShare Advisors LLC bought a new position in shares of BioLife Solutions in the fourth quarter worth $282,000. Finally, Millennium Management LLC grew its position in shares of BioLife Solutions by 49.1% in the fourth quarter. Millennium Management LLC now owns 1,145,347 shares of the medical equipment provider's stock valued at $29,733,000 after purchasing an additional 377,111 shares in the last quarter. 93.24% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on BLFS. Northland Securities upped their target price on shares of BioLife Solutions from $28.00 to $31.00 and gave the stock an "outperform" rating in a report on Wednesday, January 8th. HC Wainwright raised their price objective on BioLife Solutions from $27.00 to $30.00 and gave the company a "buy" rating in a research note on Thursday, March 6th. Benchmark reaffirmed a "buy" rating and set a $30.00 price objective on shares of BioLife Solutions in a report on Thursday, December 19th. Finally, KeyCorp raised their price target on shares of BioLife Solutions from $30.00 to $33.00 and gave the company an "overweight" rating in a research report on Friday, December 13th. One research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $29.86.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.